Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.

Discover the current pipeline candidates advancing through the clinic for the treatment of sickle cell disease.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

According to Coherent Market Insights (CMI), the global sickle cell disease treatment market size is expected to expand from USD 3.20 Bn in 2025 to USD 8.81 Bn by 2032, recording a CAGR of 15.6% ...

Google has released its most advanced AI video generator, Veo 3, to developers, launching a paid preview today through the ...